Stage in Biological Technology

Next Stage Solutions Announces Three New Financial Services For Emerging Business

Next Stage Solutions, Inc. has expanded its financial services offerings to further meet the needs of emerging businesses. Specifically, Next Stage Solutions (NSS) has launched three new services: First, CFO on Demand - NSS partners with their clients acting as an outsourced CFO on an as-needed ...

Index Ventures Closes Euro 350 Million Early Stage Fund

Ben Holmes Named Partner LONDON, March 3 /PRNewswire/ -- Index Ventures today announced the closing of a euro 350 million early stage fund, Index Ventures V. The fund is dedicated to early stage and seed investments in the technology, biotechnology and clean technology sectors across Europ...

News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009

Industry leaders, experts and foreign ministry delegations set to be involved in Asia Pacific's largest homeland security Conference and Exhibition. Singapore (PRWEB) March 2, 2009 -- Asia-Pacific's largest and most comprehensive homeland security and counter terrorism ...

Implicit Licenses Clinical Stage Antibody Program From Lilly

BRISBANE, Australia and SEATTLE, Feb. 24 /PRNewswire/ -- Implicit Bioscience Ltd today announced the acquisition of the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive ...

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study

-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles- TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that its lead product candidate bavituximab achieved th...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that it has entered the second stage of patient recruitment for its Phase 2 trial in endometrial cancer wi...

Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial

- Planned Cohort of 21 Patients with Non-Small Cell Lung Cancer Enrolled in First Stage of Trial Assessing Regimen of Bavituximab with Carboplatin and Paclitaxel - TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a ...

FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma

KENILWORTH, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Peg-IFN (peginterferon alfa-2b) supplemental Biologics License Application (sBLA) for review and has granted Priority ...

Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer

Oral Presentation of the US Oncology Adjuvant Trial 9735 at 2007 San Antonio Breast Cancer Symposium Showed Taxotere(R) and Cyclophosphamide Improved Overall Survival Versus An Anthracycline Combination SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ -- Results presented at the 30th annual...

National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications

This development places National Stem Cell in the sector for Anti-aging products and services, presently a $30 Billion Market, and one of the Biggest Marketing Opportunities in the U.S. Today MOUNTAINSIDE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (O...

Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings

-- Further analysis of phase 2 breast cancer data show preferential activity of adecatumumab on inhibiting the formation of new metastases -- Results from 169 patients treated with adecatumumab demonstrate an apparent lack of immunogenicity of the antibody BETHESDA, Md., Oct...

OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye

MIAMI, Oct. 10 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK ) today announced that it has acquired exclusive worldwide rights for ophthalmic uses to a topical clinical stage compound with potential utility in the treatment of dry eye. "Dry eye is an increasingly common condition tha...

HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica

SAN DIEGO and SHANGHAI, China, Oct. 2 /PRNewswire/ -- HUYA Bioscience International (HUYA), a rapidly expanding biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic com...

Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading

BEIJING and CLAREMONT, Calif., Sept. 26 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) today announced that its wholly owned subsidiary, Kiwa Bio-Tech Products (Shandong) Co., Ltd., has completed the first stage of the planned upgrading of ...

Neah Power Systems A seed stage venture capital model

Developing a viable technology company requires insight, discipline, and a relentless focus on developing technology, business and marketing plans. Many successful startups create a high-value company by defining a big problem with a large focused market opportunity for the development of new produ...

An analysis of Wisconsins new venture capital and early stage finance programs

If high tech is the engine of future economic growth, Wisconsin is running low on investment fuel. A recent study by the California-based Milken Institute ranks our state 32nd out of 50 in availability of the risk capital that technology entrepreneurs need to turn innovative ideas into marketplace...

With Sarbanes-Oxley, compliance takes center stage for CIOs

If, five years ago, you asked a group of chief information officers for their number-one issue, they might have said storage capacity, security or bandwidth. Today, the consensus issue is compliance, particularly with the new spate of securities legislation, highlighted by Congress's passage of ...

Early Stage Symposium session will help emerging companies prepare for investors

Madison, Wis. - Companies that register for the Oct. 19-20 Wisconsin Early Stage Symposium may attend a seminar that will help them prepare to seek private equity at the state, regional and even national level. "Venture Readiness Tools for Commercialization Success" will be held Oct. 20 as a ...

Early Stage Step 2: Choosing a domain name

Editor's note: This is the second in a series of articles on developing start-up companies in the technology or biotechnology realm. The first edition of Early Stage focused on protecting your intellectual property. Madison, Wis. - So now that you know you have a patentable technology or...

Early Stage 7, Part I: Just what is an employee?

Editor's note: This is the seventh in a series of articles on developing start-up companies in the technology or biotechnology sectors. The most recent article focused on business taxes. Madison, Wis. - Your entity is formed and you are ready to begin hiring workers. As discussed in the pr...

Early Stage 10: The nuances of federal laws

Editor's note: This is the 10th in a series of articles on developing start-up companies in the technology or biotechnology sectors. Madison, Wis. - In Step 9 we discussed general concepts on the securities laws. This time we focus specifically on the federal laws. Any business that of...

Internet-enabled niche markets take center stage

Madison, Wis. - Whether you pronounce it nitch or the more cosmopolitan neesh, the term niche is spelled the same way, and thanks in large measure to the Internet, it increasingly spells growth and profit. An entire conference, Brandworks University 2007 , is centered on what some are calling...

Growth spurts

...or on a paper that reported these results in the journal Science. "In our study, we found that coalescence events are frequently involved in the early stage of nanocrystal growth and yet monodisperse nanocrystals are still formed." Says Alivisatos, a chemist who holds joint appointments with Berkeley La...

SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results

...ties up to an aggregate public offering price of $40 million. However, the financial markets have been very difficult for companies at our development stage and financial condition and financing may not be available on favorable terms or at all. Additionally, we have received notice from the NYSE Amex that...

Novavax Reports Second Quarter 2009 Financial Results

..., other non-dilutive financing, or additional partnering agreements, as opportunities arise. About Novavax Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particl...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

...nd $112,524, respectively. As a development stage biopharmaceutical company, Catalyst has no revenue..., INC. (a development stage company) CONDENSED STATEMENTS O..., INC. (a development stage company) CONDENSED B...

NeurogesX Reports Second Quarter 2009 Results

...painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate ...rther development efforts. NeurogesX' early stage product pipeline includes pre-clinical compounds, ...X, INC. (A Development stage Company) Condensed Consolidated...

Telik Announces Second Quarter 2009 Financial Results

...luding restricted investments, compared to $63.5 million at December 31, 2008. About Telik Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most adv...

PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan

...he field of Alzheimer's drug development," says Dr. Fillit. "At ADDF, we are about results - bridging the gap between basic research and later stage drug development in humans. Alzheimer's is the fifth leading cause of death in the elderly and the third most costly disease overall. We're seeking to...

The Breast Cancer Therapeutics Market in Australia

... detection of breast cancer, have resulted in oncologists seeing more early stage disease. This, combined with aggressive and targeted therapy has, in turn, ...ts Scheme (PBS)," says Gaffud. Currently, only Herceptin (for early stage breast cancer patients) and Tykerb (for advanced/metastatic breast cancer p...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

...neuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal pat...e design and timing of further development efforts. NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of ace...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...le-blind, randomized, placebo-controlled treatment stage and will enroll approximately 60 subjects who are ...t all stages of a company's development, from seed stage through IPO. With approximately $8.5 billion in co...ics, Inc. (a development stage company) Consolidated Statem...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

... CADENCE PHARMACEUTICALS, INC. (a development stage company) CONDENSED STATEMENTS OF OPERATIONS ... CADENCE PHARMACEUTICALS, INC. (a development stage company) CONDENSED BALANCE SHEETS ...

Pharmasset to Present at Canaccord Adams Conference

...ys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which recently began Phase 1 clinical studies and Racivir, for the trea...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

... the 2009 ASCO annual meeting. Results demonstrated that the Onco type DX colon cancer test can independently predict individual recurrence risk for stage II colon cancer patients following surgery. Importantly, the Onco type DX colon cancer Recurrence Score(R) provided additional independent clinical v...

Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level

...nder of ELARA Pharmaceuticals. "The discovery support from ChemPartner helped our Hypoxia Signaling inhibitor program to move from academic discovery stage to early proof of concept. This led to a successful spin off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Our new in...

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

...velopment of new antiviral agents against novel targets for the treatment of hepatitis virus infections. Eiger's pipeline includes repurposed clinical stage therapeutic agents as well as preclinical NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eig...

OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.

...cal trials. Phase I clinical trials are the first stage of the US or International regulatory approval pro...ster(R) software, which is primarily used in later stage clinical trials. The Logos products cover all aspe...sample management. Regular EDC solutions for later stage trials do not include a pro-active data collection...

Biotech Hot in July Driven by Positive Drug Data and Acquisitions

... a 90 percent premium. With the acquisition Bristol-Myers Squibb gains full rights to ipilimumab, an experimental drug for metastatic melanoma in late stage testing. The companies together have been developing the drug, which is also being studied in lung and prostate cancers. Bristol also gains rights to ...

Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

...ars as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC). As o...se progression. Nine of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a co...